Prestige Biopharma (PBP) is an innovative biopharmaceutical company specializing in the discovery and development of innovative biologics and biosimilars. PBP1510 (Ulenistamab) is the First-in-Class Pancreatic Cancer drug which is on the stage of 1/2a global clinical phase. Based on our innovative biomarker, PAUF, we are continuing the challenge for overcoming hard-to-treat diseases such as pancreatic cancer. We are developing biosimilars to contribute on the patient's drug accessibility. Over 12 biosimilars we have been developing since 2015. And also, we are expanding the application of PAUF biomarker to the diagnostics. To expand the effectiveness of pancreatic cancer treatment, we are developing the diagnostic device. The primary focus of current PBP’s R&D is oncology and immune disorders, developing new and similar antibody drugs for solid tumor, pancreatic cancer, and arthritis. In parallel with our efforts to enhance safety, efficacy, and affordability of existing antibody therapeutics, PBP thrives to search for new targets and candidates with a goal to free mankind from devastating diseases Established on core values cherishing life and fostering the spirit of philanthropy, Prestige BioPharma promises to grow everyday to make our dream come true.
